CD15

CHERATINE CK7 - CK20

PRINCIPALI LETTURE CONSIGLIATE

Il primo articolo generale apparso sull’argomento e’:

Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM.

Coordinate expression of cytocheratins 7 and 20 defines unique subsets of carcinomas.

Appl Immunohistochem 3 (2): 99-107, 1995.

Per chi si diletta di francese, un buon articolo e’ quello di Leroy et al. che riassume alcune delle principali problematiche diagnostiche differenziali

Leroy X, Copin M-C. Boman F. Gosselin B.

Les cytokeratines 7 and 20: aide au typage des tumeurs.

Ann Pathol. 1998, 18 (2), 103-109.

°°°

Per una rapida e aggiornata visone generale del problema si puo’ leggere il seguente articolo che compara i risultati immunoistochimici su una propria ampia casistica e si confronta con i dati del lavoro di Wang et al.

Chu P, Wu E, Weiss LM.

Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.
Mod Pathol 2000 Sep;13(9):962-72

Division of Pathology, City of Hope National Medical Center, Duarte, California 91010, USA.
Cytokeratin 7 (CK 7) and cytokeratin 20 (CK 20) are low molecular weight cytokeratins. Their anatomic distribution is generally restricted to epithelia and their neoplasms. We surveyed 435 epithelial neoplasms from various organ systems by immunohistochemistry using CK 7 and CK 20 monoclonal antibodies. Expression of CK 7 was seen in the majority of cases of carcinoma, with the exception of those carcinomas arising from the colon, prostate, kidney, and thymus; carcinoid tumors of the lung and gastrointestinal tract origin; and Merkel cell tumor of the skin. The majority of cases of squamous cell carcinoma of various origins were negative for CK 7, except cervical squamous cell carcinoma, in which 87% of cases were positive. Approximately two thirds of cases of malignant mesothelioma were CK 7-positive. CK 20 positivity was seen in virtually all cases of colorectal carcinomas and Merkel cell tumors. CK 20-positive staining was also observed in cases of pancreatic carcinomas (62%), gastric carcinoma (50%), cholangiocarcinomas (43%), and transitional cell carcinomas (29%). The expression of CK 20 was virtually absent in carcinomas from other organ systems and in malignant mesothelioma. CK 7- and CK 20-negative epithelial neoplasms included adrenal cortical carcinoma, germ cell tumor, prostate carcinoma, renal cell carcinoma, and hepatocellular carcinoma.

Chi invece si chiede quali applicazioni possano avere in citologia può riferirsi allo studio di Blumenfeld et al. su 51 casi.

Diagn Cytopathol 1999 Feb;20(2):63-6

Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens.
Blumenfeld W, Turi GK, Harrison G, Latuszynski D, Zhang C.
Department of Pathology, Winthrop-University Hospital, Mineola, New York 11501, USA. wblumen@pathology.winthrop.org
This study was undertaken to assess the utility of combined cytokeratin (CK) 7/20 immunoprofile determination in malignant cytologic cell blocks as an aid to the identification of tumor primary site of origin. Fifty-one cases in which CK 7/20 immunocytochemistry was performed as part of the initial workup were retrieved. Their contribution to the final cytologic diagnosis of tumor primary site of origin was analyzed. CK reactivity patterns were 7+/20- (n = 34), 7-/20+ (n = 9), 7-/20- (n = 7), and 7+/20+ (n = 1). The CK 7+/CK 20- immunophenotype was the most common one obtained, and due to its wide expression in a number of common carcinomas, the least informative. The second most common immunophenotype was CK 7-/20+, which is associated with colorectal origin, and as such was very useful when obtained. The CK immunoprofile was more useful in the setting of a prior carcinoma, being a major diagnostic determinant in 13 cases (55%) from group 1 (those with a prior history of malignancy), compared to 8 cases (29%) from group 2 (those with no prior history of malignancy). In the setting of prior carcinoma, the CK immunoprofile is most useful when carcinomas under consideration have different expected immunoprofiles (e.g., CK 7+/CK20- carcinomas, including lung, breast, ovary, endometrium, and others, vs. CK 7-/CK 20+ carcinomas, primarily colorectal). When similar immunoprofiles are obtained, their usefulness is greater if they are immunoprofiles other than the most common 7+/20- pattern. Similarly, in newly diagnosed carcinomas, the CK immunoprofile either helps to narrow the differential diagnosis or points to a specific diagnosis.